Bioxcel Therapeutics Logo-9.17.21.png
BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery and Development and Advances in Neuroscience Portfolio at Virtual R&D Day
September 23, 2021 07:00 ET | BioXcel Therapeutics
Management to showcase AI platform to develop potential treatments for neuropsychiatric disorders Company to introduce BXCL502 program and discuss expansion opportunities for lead program, BXCL501 ...
bioxcel-therapeutics-local-250x100.jpg
BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO
September 15, 2021 18:06 ET | BioXcel Therapeutics
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma BXCL701 combination continues to exhibit favorable safety...
bioxcel-therapeutics-local-250x100.jpg
BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress
September 12, 2021 18:05 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Sept. 12, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
bioxcel-therapeutics-local-250x100.jpg
BioXcel Therapeutics to Host Virtual R&D Day on September 23, 2021
September 09, 2021 07:00 ET | BioXcel Therapeutics
Live webcast, Revolutionizing Drug Discovery and Development Through AI, to be held from 12:00 PM ET – 2:00 PM ET NEW HAVEN, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc....
bioxcel-therapeutics-local-250x100.jpg
BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
August 10, 2021 07:00 ET | BioXcel Therapeutics
Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021 PDUFA date of January 5, 2022 assigned to BXCL501 NDA for the acute treatment of...
bioxcel-therapeutics-local-250x100.jpg
BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021
July 28, 2021 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., July 28, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
bioxcel-therapeutics-local-250x100.jpg
BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
July 19, 2021 07:30 ET | BioXcel Therapeutics
NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive...
Bioxcel Therapeutics - logo-300X70.jpg
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
June 23, 2021 08:29 ET | BioXcel Therapeutics
NEW HAVEN, Conn., June 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of...
Bioxcel Therapeutics - logo-300X70.jpg
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
June 22, 2021 16:01 ET | BioXcel Therapeutics
NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches...
Bioxcel Therapeutics - logo-300X70.jpg
BioXcel Therapeutics to Host Virtual Commercial Day on June 25, 2021
June 18, 2021 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., June 18, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...